

Print / eNewsletter

CONNECT:

- HOME
- INDUSTRY ANALYSIS
- BUSINESS STRATEGY
- HEALTH MANAGEMENT
- HOSPITALS & PROVIDERS
- PHARMACY BEST-PRACTICES
- TECHNOLOGY



ADVERTISEMENT

- ING: Diabetes Health Management Pop Health Revenue Cycle Management NAMCP AMCP

**PREV** Cognitive computing shakes up healthcare: Wha ...

Managed Healthcare Executive Benchmarks

## When given the chance, will patients choose cheaper prescription drugs?

August 26, 2017

By Tracey Walker

### Reference pricing results

Reference pricing is a response to the wide and unjustified variability in prices charged for similar drugs (and other medical services), according to Robinson.

“Under reference pricing, the employer or insurer sets a maximum payment it will contribute towards the price of drugs within each therapeutic class, pegging that level to the lowest or one of the lowest charged within the class,” he explains. “Patients who select the low-priced ‘reference’ drug pay only a modest \$10 copay per prescription—rather than high copayments or coinsurance often found in tiered drug formularies.”

However, if the patient continues to prefer a more expensive drug, he or she must pay the full difference, according to Robinson. “If the patient’s doctor believes the patient needs to expensive drug for a clinical reason, the extra cost sharing is waived—the patient is exempted from reference pricing,” he says.

“For self-funded plan sponsors or purchasers, prescription drug reference pricing is a strategy that can measurably lower the non-specialty drug spend and stabilize the overall rating trend,” says Henka. RxTE identifies drugs within a specific medication group that are therapeutic equivalents and clinically interchangeable.

RESOURCE CENTERS PARTNER CONTENT

- Pop Health Resource Center
- Ovarian and Breast Cancer Resource Center
- Diabetes Health Management
- Revenue Cycle Management: Billing & Collections
- Meaningful Use 2

[MORE](#)

FOLLOW US ON TW

philosophical orientation  
and physicians to  
at the right price.”

PUBLICATIONS

BUSINESS

EDUCATION

CAREERS

CONTACT US  
@MHEEXECUTIVE

LOG IN / REGISTER  
FOLLOW US

Therapeutic substitutions are based on therapeutic equivalence and can only be made when the doctor (and patient) agrees to make the switch. RxTE's prescription reference pricing leverages the importance of doctor/ patient relationship to facilitate an informed and medically directed choice. Reference pricing isn't new, many European nations use reference pricing as a method to mitigate increases in pharmaceutical spending.

Based on this study, Robinson has three takeaways:

1. Consider reference pricing as a supplement or alternative to the traditional tiered formulary approach to managing drug choice and cost.
2. Unlink the consumer's cost sharing (e.g. deductible) from the list price of the drug, when the PBM and insurer (but not the patient) receive negotiated price rebates. "A consumer and regulatory backlash is coming," Robinson says.
3. Don't just expose patients to 'naked' high-deductible designs. "Offer them easy to identify low-priced options—help them save money—while making them responsible for the extra costs if they continue to select the more expensive options," Robinson says.



FIND US ON FACEBOOK

**Managed Healthcare**  
The C-Suite Advisor EXECUTIVE

Find us on

GO NOW

LATEST TWEETS

**Managed Healthcare @MHEExecutive** 28 Aug  
Elder Abuse: ERs Learn How To Protect A Vulnerable Population  
<https://t.co/95KkFLTopB>

**Managed Healthcare @MHEExecutive** 27 Aug  
Views split on #populationhealth benefits  
<https://t.co/eiQqynk0M6>  
<https://t.co/MhTAIXvCiu>

Tweet to @MHEExecutive

- TAGS
- Benchmarks
  - benchmarks
  - Benefit design and pricing
  - Drug costs
  - Member engagement
  - MHE Articles
  - PBM
  - prescription costs
  - prescription drug costs
  - Reference-based pricing
  - RxTE

Tracey Walker

MORE

**Managed Healthcare**  
EXECUTIVE  
eNews



Sign up here

0 COMMENTS

You must be signed in to leave a comment. Registering is fast and free!

SIGN IN / REGISTER

in whole or in part, in any  
FAQ.

No comments available

BUSINESS &  
TECHNOLOGY

WOMEN'S  
HEALTH

CHILDREN'S  
HEALTH

MEN'S  
HEALTH

SKIN

PHARMACY

EYECARE

HEART  
HEALTH

Managed Healthcare  
EXECUTIVE

HOME

INDUSTRY ANALYSIS

BUSINESS  
STRATEGY



HEALTH  
MANAGEMENT

HOSPITALS &  
PROVIDERS

PHARMACY BEST-  
PRACTICES

TECHNOLOGY

CONNECT:



[About Managed Healthcare Executive](#) | [Contact Us](#) | [About Us](#) | [Advertise with Us](#) | [All Content](#) | [Modern Medicine Managed Care](#) | [Privacy Policy](#) | [Terms of Use](#) | [Advertiser terms](#) | [Linking and RSS Policy](#)

© 2017 UBM Medica, LLC, a UBM company.

Reproduction in whole or in part is prohibited.

Please send any technical comments or questions to our webmaster.